CDXS
Price
$5.19
Change
-$0.44 (-7.82%)
Updated
Dec 18, 04:59 PM (EDT)
70 days until earnings call
TBPH
Price
$9.73
Change
-$0.23 (-2.31%)
Updated
Dec 18, 04:59 PM (EDT)
75 days until earnings call
Ad is loading...

CDXS vs TBPH

Header iconCDXS vs TBPH Comparison
Open Charts CDXS vs TBPHBanner chart's image
Codexis
Price$5.19
Change-$0.44 (-7.82%)
Volume$17.92K
CapitalizationN/A
Theravance Biopharma
Price$9.73
Change-$0.23 (-2.31%)
Volume$1.33K
CapitalizationN/A
CDXS vs TBPH Comparison Chart
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. TBPH commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a Hold and TBPH is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CDXS: $5.63 vs. TBPH: $9.96)
Brand notoriety: CDXS and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 132% vs. TBPH: 131%
Market capitalization -- CDXS: $456.53M vs. TBPH: $489.78M
CDXS [@Biotechnology] is valued at $456.53M. TBPH’s [@Biotechnology] market capitalization is $489.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, TBPH is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 3 TA indicator(s) are bullish while TBPH’s TA Score has 4 bullish TA indicator(s).

  • CDXS’s TA Score: 3 bullish, 4 bearish.
  • TBPH’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CDXS is a better buy in the short-term than TBPH.

Price Growth

CDXS (@Biotechnology) experienced а -0.71% price change this week, while TBPH (@Biotechnology) price change was -1.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

CDXS is expected to report earnings on Feb 26, 2025.

TBPH is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TBPH($478M) and CDXS($458M) have the same market capitalization . CDXS YTD gains are higher at: 84.590 vs. TBPH (-11.388). CDXS has higher annual earnings (EBITDA): -30.09M vs. TBPH (-33.83M). TBPH (91.4M) and CDXS (90.3M) have equal amount of cash in the bank . CDXS has less debt than TBPH: CDXS (41.8M) vs TBPH (45M). CDXS (64.4M) and TBPH (63.2M) have equivalent revenues.
CDXSTBPHCDXS / TBPH
Capitalization458M478M96%
EBITDA-30.09M-33.83M89%
Gain YTD84.590-11.388-743%
P/E RatioN/AN/A-
Revenue64.4M63.2M102%
Total Cash90.3M91.4M99%
Total Debt41.8M45M93%
FUNDAMENTALS RATINGS
CDXS vs TBPH: Fundamental Ratings
CDXS
TBPH
OUTLOOK RATING
1..100
2918
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
38
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
3548
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TBPH's Valuation (38) in the Pharmaceuticals Other industry is in the same range as CDXS (58) in the Chemicals Specialty industry. This means that TBPH’s stock grew similarly to CDXS’s over the last 12 months.

TBPH's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that TBPH’s stock grew similarly to CDXS’s over the last 12 months.

TBPH's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as CDXS (98) in the Chemicals Specialty industry. This means that TBPH’s stock grew similarly to CDXS’s over the last 12 months.

CDXS's Price Growth Rating (35) in the Chemicals Specialty industry is in the same range as TBPH (48) in the Pharmaceuticals Other industry. This means that CDXS’s stock grew similarly to TBPH’s over the last 12 months.

CDXS's P/E Growth Rating (100) in the Chemicals Specialty industry is in the same range as TBPH (100) in the Pharmaceuticals Other industry. This means that CDXS’s stock grew similarly to TBPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSTBPH
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 9 days ago
74%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 7 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Ad is loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TBPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PPYIX7.76N/A
N/A
PIMCO RAE International Instl
RTOUX44.18N/A
N/A
Russell Inv Tax-Managed US Mid&Sm Cap M
MECVX15.09-0.10
-0.66%
NYLI Epoch Capital Growth Investor Class
TESIX27.16-0.20
-0.73%
Franklin Mutual Shares A
WQAUX11.73-0.09
-0.76%
Westwood Quality AllCap Ultra

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with DNLI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+0.36%
DNLI - CDXS
49%
Loosely correlated
-0.30%
BEAM - CDXS
45%
Loosely correlated
-1.21%
ABCL - CDXS
43%
Loosely correlated
-2.45%
AXON - CDXS
43%
Loosely correlated
-2.09%
PLRX - CDXS
42%
Loosely correlated
+4.74%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with AXON. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
+1.63%
AXON - TBPH
34%
Loosely correlated
-2.09%
ARRY - TBPH
34%
Loosely correlated
+6.01%
MDGL - TBPH
30%
Poorly correlated
-1.58%
CDXS - TBPH
30%
Poorly correlated
+0.36%
ELEV - TBPH
29%
Poorly correlated
+4.66%
More